Turn Therapeutics is a pharmaceutical company that is dedicated to reducing the human and economic costs of infection and skin disease.
Turn Therapeutics has raised $7.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in March 2026.
Turn Therapeutics's investors include Avenue Capital Group, The Global Emerging Markets Group, Suriyaa Sundararuban.
Turn Therapeutics is headquartered in Calabasas, United States.
Turn Therapeutics is a pharmaceutical company that is dedicated to reducing the human and economic costs of infection and skin disease.
Turn Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Turn Therapeutics — Funding & Investors." VCBacked, March 24, 2026, https://www.vcbacked.co/company/turn-therapeutics. Accessed August 18, 2026.
VCBacked. (2026). Turn Therapeutics — Funding & Investors. Retrieved August 18, 2026, from https://www.vcbacked.co/company/turn-therapeutics
{{cite web |title=Turn Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/turn-therapeutics |website=VCBacked |access-date=August 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated